Telmisartan [144701-48-4]

Telmisartan is an angiotensin II receptor antagonist that has been widely utilized in scientific research to investigate the renin-angiotensin-aldosterone system and its role in cardiovascular physiology and disease. Its mechanism of action involves blocking the binding of angiotensin II to its receptors, leading to relaxation of blood vessels and an increase in sodium excretion by the kidneys. Researchers have employed Telmisartan to study the effects of angiotensin II on various physiological processes, such as blood pressure regulation, electrolyte balance, and kidney function. Additionally, Telmisartan has been used to develop novel bioanalytical methods and affinity probes for the detection and quantification of angiotensin II and its receptors. Its specific mechanism of action has also been exploited to investigate the molecular mechanisms underlying cardiovascular disease, including hypertension and cardiac hypertrophy. Furthermore, Telmisartan has been used to explore the interactions between the renin-angiotensin-aldosterone system and other physiological pathways, providing valuable insights into the complex regulation of cardiovascular function.

Telmisartan (CAS 144701-48-4) Références:

1. Telmisartan in high-risk cardiovascular patients.  |  Weber, MA. 2010. Am J Cardiol. 105: 36A-43A. PMID: 20102972
2. Fenofibrate and Telmisartan in the Management of Abdominal Aortic Aneurysm.  |  Rowbotham, SE., et al. 2018. Curr Drug Targets. 19: 1241-1246. PMID: 29284388
3. Telmisartan inhibits oxalate and calcium oxalate crystal-induced epithelial-mesenchymal transformation via PPAR- gamma -AKT/STAT3/p38 MAPK-Snail pathway.  |  Liu, Y., et al. 2020. Life Sci. 241: 117108. PMID: 31786192
4. Telmisartan-induced sprue-like enteropathy: a case report.  |  Alzueta, N., et al. 2020. Eur J Hosp Pharm. 27: 49-51. PMID: 32064089
5. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.  |  Rothlin, RP., et al. 2020. Drug Dev Res. 81: 768-770. PMID: 32356926
6. Efficacy of telmisartan for the treatment of persistent renal proteinuria in dogs: A double-masked, randomized clinical trial.  |  Lourenço, BN., et al. 2020. J Vet Intern Med. 34: 2478-2496. PMID: 33165969
7. Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior.  |  Huber, G., et al. 2021. J Cereb Blood Flow Metab. 41: 2356-2369. PMID: 33730932
8. Effect of telmisartan, angiotensin-converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs.  |  Fowler, BL., et al. 2021. J Vet Intern Med. 35: 1231-1237. PMID: 33769606
9. Treatment of proteinuria in dogs with telmisartan: Aretrospective study.  |  Lecavalier, J., et al. 2021. J Vet Intern Med. 35: 1810-1818. PMID: 33969924
10. Telmisartan anti-cancer activities mechanism through targeting N-cadherin by mimicking ADH-1 function.  |  Khorsand, M., et al. 2022. J Cell Mol Med. 26: 2392-2403. PMID: 35224849
11. Telmisartan is the most effective ARB to increase adiponectin via PPAR alpha in adipocytes.  |  Hattori, N., et al. 2022. J Mol Endocrinol. 69: 259-268. PMID: 35354667
12. Telmisartan ameliorates LPS-induced pneumonia in rats through regulation of the PPAR gamma /NF- kappa B pathway.  |  Zhou, X., et al. 2022. Microbiol Immunol. 66: 371-378. PMID: 35485217
13. MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells.  |  Yamana, Y., et al. 2022. J Cancer Res Ther. 18: S305-S312. PMID: 36510981
14. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277.  |  Wienen, W., et al. 1993. Br J Pharmacol. 110: 245-52. PMID: 8220885
15. Telmisartan.  |  McClellan, KJ. and Markham, A. 1998. Drugs. 56: 1039-44; discussion 1045-6. PMID: 9878991

Modulation Targets

Inhibitor of: AT1.
Activator of: PPAR gamma.